SCHEDULE: Millennium Management Discloses ALX Oncology Stake

Millennium Management and affiliated entities report a 1.5% beneficial ownership stake in ALX Oncology Holdings Inc.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander filed a Schedule 13G amendment regarding their holdings in ALX Oncology.
• The reporting persons collectively beneficially own 1,988,559 shares of ALX Oncology common stock.
• This represents approximately 1.5% of the company's outstanding common stock.
• Integrated Core Strategies (US) LLC, a subsidiary, holds 730,528 of these shares, representing 0.5% of the class.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory disclosure of passive investment activity with no direct impact on company operations.

Positives

• Institutional interest from a major investment firm like Millennium Management often signals market confidence in the issuer's long-term prospects.

Negatives

• The filing indicates a relatively small ownership position (1.5%), which does not constitute a controlling interest or a significant activist stake.

Risks

• The filing notes that the securities were not acquired for the purpose of changing or influencing the control of the issuer, limiting the potential for immediate strategic intervention by these shareholders.

Future Outlook

The reporting persons have certified that the shares were not acquired for the purpose of changing or influencing the control of the issuer, suggesting a passive investment strategy.

Industry Context

StockSavvy.ai notes that Schedule 13G filings by large multi-strategy hedge funds like Millennium are standard disclosures of passive investment activity in the biotechnology sector, reflecting portfolio rebalancing rather than specific corporate strategic shifts.

Comparison to Industry Standards

• The 1.5% stake is consistent with typical passive institutional holdings in mid-cap biotechnology firms.
• The filing follows standard SEC regulatory requirements for institutional investors exceeding certain reporting thresholds.

Stakeholder Impact

• Minimal impact on shareholders as the filing confirms a passive investment stance.

Next Steps

• Continued monitoring of future 13G or 13F filings to track changes in institutional ownership levels.

Key Dates

Keywords

ALX Oncology, Millennium Management, Schedule 13G, Institutional Ownership, Biotech, Common Stock